Ueno T - Search Results

1

Chromatin conformational changes at human satellite II contribute to the senescence phenotype in the tumor microenvironment.

Miyata K, Zhou X, Nishio M, Hanyu A, Chiba M, Kawasaki H, Osako T, Takeuchi K, Ohno S, Ueno T, Maruyama R, Takahashi A. Miyata K, et al. Among authors: ueno t. Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2305046120. doi: 10.1073/pnas.2305046120. Epub 2023 Jul 31. Proc Natl Acad Sci U S A. 2023. PMID: 37523559 Free PMC article.

2

Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients.

Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K, Tomita M, Eishi Y. Horiguchi K, et al. Among authors: ueno t. J Med Dent Sci. 2010 Jun;57(2):165-75. J Med Dent Sci. 2010. PMID: 21073135

3

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.

Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S. Aogi K, et al. Among authors: ueno t. Breast Cancer Res Treat. 2011 Oct;129(3):829-38. doi: 10.1007/s10549-011-1685-x. Epub 2011 Jul 31. Breast Cancer Res Treat. 2011. PMID: 21805309 Clinical Trial.

4

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Ueno T, et al. BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9. BMC Cancer. 2016. PMID: 26984766 Free PMC article. Clinical Trial.

5

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: ueno t. Cancer Med. 2018 Jul;7(7):3044-3056. doi: 10.1002/cam4.1600. Epub 2018 Jun 14. Cancer Med. 2018. PMID: 29905023 Free PMC article.

6

Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast.

Yonekura R, Osako T, Iwase T, Ogiya A, Ueno T, Kitagawa M, Ohno S, Akiyama F. Yonekura R, et al. Among authors: ueno t. Breast Cancer Res Treat. 2019 Feb;174(1):103-111. doi: 10.1007/s10549-018-5068-4. Epub 2018 Nov 24. Breast Cancer Res Treat. 2019. PMID: 30474777

7

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: ueno t. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. Cancer Med. 2019. PMID: 31361400 Free PMC article. Clinical Trial.

8

Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence.

Sato A, Sakai T, Iwase T, Kano F, Kimura K, Ogiya A, Koizumi M, Tanabe M, Horii R, Akiyama F, Ueno T, Ohno S. Sato A, et al. Among authors: ueno t. Radiat Oncol. 2019 Sep 2;14(1):159. doi: 10.1186/s13014-019-1367-0. Radiat Oncol. 2019. PMID: 31477153 Free PMC article.

9

Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature.

Luangxay T, Osako T, Yonekura R, Sugiura Y, Kikuchi M, Gomi N, Ueno T, Ohno S, Machinami R, Takeuchi K, Akiyama F. Luangxay T, et al. Among authors: ueno t. Pathol Res Pract. 2020 Feb;216(2):152750. doi: 10.1016/j.prp.2019.152750. Epub 2019 Nov 19. Pathol Res Pract. 2020. PMID: 31784095 Review.

10

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.

Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Ueno T, et al. Jpn J Clin Oncol. 2020 Jan 24;50(1):3-11. doi: 10.1093/jjco/hyz119. Jpn J Clin Oncol. 2020. PMID: 31821506 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,452 results

Search Page